RANI insider trading
NasdaqGM HealthcareRani Therapeutics Holdings, Inc.: insider trade history from SEC Form 4 filings.
About Rani Therapeutics Holdings, Inc.
Rani Therapeutics Holdings, Inc. operates as a clinical stage biotherapeutics company, focusing on technologies to enable the administration of biologics and drugs orally for patients, physicians, and healthcare systems with a alternative to painful injections in the United States. The company develops the RaniPill capsule, a drug-agnostic oral delivery platform to deliver a variety of drug substances, including oligonucleotides, peptides, proteins, and antibodies. Its product pipeline includes RT-102, a parathyroid hormone that is in Phase I clinical trial for the treatment of osteoporosis; RT-105, an anti-TNF-alpha antibody that is in preclinical studies to treat psoriatic arthritis; RT-110, a parathyroid hormone for the treatment of hypoparathyroidism; RT-116 which is in discovery stage for the treatment of obesity; and RT-111, an ustekinumab biosimilar for the treatment of various inflammatory conditions. The has a collaboration agreement with ProGen Co., Ltd. for the o-development and commercialization of RT-114 to treat obesity. Rani Therapeutics Holdings, Inc. was founded in 2012 and is headquartered in San Jose, California.
Company website: www.ranitherapeutics.com
RANI insider activity at a glance
FilingIQ tracks 141 insider transactions for RANI in filings since Aug 3, 2021. The most recent transaction is dated Sep 27, 2026.
Across the full history, 87 open-market purchases
and 11 open-market sales
were filed under transaction codes P and S respectively. Compensatory share awards
(code A) and option exercises (code M) are tracked separately and not counted here.
How FilingIQ classifies each line, and the seven facts it shows on every open-market purchase and sale, are documented on the methodology page.
Latest RANI Form 4 filings
Most recent disclosures. Sign up to filter by transaction code, insider role or dollar value.
Other Healthcare tickers with recent insider activity
Frequently asked
- How many insider trades does FilingIQ track for RANI?
- FilingIQ tracks 141 Form 4 insider transactions for RANI (Rani Therapeutics Holdings, Inc.), covering filings from Aug 3, 2021 onwards. 3 of those are dated within the last 90 days.
- Are RANI insiders net buyers or net sellers?
- Across the full Form 4 history for RANI, 87 transactions (62%) were open-market purchases and 11 (8%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.
- Where does RANI insider data come from?
- Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ links every filing to the insider's SEC CIK, marks plan trades, tax withholding, option exercises, gifts, derivatives and amendments, and shows each open-market purchase and sale with the same fixed facts. It does not rate the stock.
- What sector is RANI in?
- Rani Therapeutics Holdings, Inc. (RANI) is classified in the Healthcare sector, specifically Biotechnology, with a current market capitalisation of $139.82M.
Methodology & sources
Every RANI insider transaction shown on FilingIQ is parsed directly from a public SEC Form 4 XML filing. Insider identity is normalised across reporting variants (CIK changes, name spellings, related-party indirect holdings). How lines are classified and which facts FilingIQ adds is documented on the methodology page; the people behind it are on the team page. Not investment advice; see disclaimer.